Indications for DALVANCE:
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
Give by IV infusion over 30 mins. CrCl ≥30mL/min or on regular hemodialysis: administer 1500mg as single dose, or 1000mg followed by 500mg one week later. Renal impairment (CrCl <30mL/min) and who are not receiving regularly scheduled hemodialysis: administer 1125mg as single dose, or 750mg followed by 375mg one week later.
History of glycopeptide allergy. Discontinue if serious hypersensitivity or skin reactions occur. Moderate or severe hepatic impairment (Child-Pugh Class B or C). Renal impairment (CrCl <30mL/min). Pregnancy (Cat.C). Nursing mothers.
Nausea, headache, diarrhea, vomiting, rash, pruritus; ALT elevations, infusion-related reactions (eg, Red-Man Syndrome), C. difficile-associated diarrhea (discontinue if occurs).
Generic Drug Availability: